Haag In Oberbayern

Researchers are evaluating the safety and effectiveness of the study drug IPN10200 compared with a placebo for treating adults with Cervical Dystonia (CD). CD causes abnormal movements and symptoms in the head and neck, including pain, stiffness, and headaches. The condition may be influenced by brain function, genetics, and environmental factors. Current treatments involve botulinum toxin (BoNT) injections lasting about three months, but IPN10200 is designed to provide longer-lasting relief. Participants will receive a single intramuscular injection of IPN10200 at one of several doses or a placebo on the first day of the 36-week treatment period. The injections will be given into muscles in the head, neck, and shoulders. Before treatment, there is a screening period lasting up to four weeks to confirm eligibility. Some participants may continue other medications during the study, with all treatments recorded. The study involves about 40 weeks of participation, including screening and treatment. Participants will attend 10 to 12 in-person clinic visits plus one remote phone visit. During these visits, they will undergo blood and urine tests, physical and neurological exams, and clinical assessments. Questionnaires will also be completed to evaluate symptoms and treatment effects. The main outcome measured is the change in cervical dystonia severity four weeks after treatment based on a standardized rating scale.

Researchers are studying severe asthma through the German Asthma Net e.V., which focuses on improving medical care and understanding of this condition. Since there is limited reliable data on how often severe asthma occurs, its characteristics, and treatment patterns, this clinical registry collects detailed information from patients across Germany. The aim is to better characterize severe asthma by gathering data from multiple clinics and practices, helping to optimize diagnosis and treatment over time. Participants in this registry have their sociodemographic details and medical information recorded, including diagnosis, therapy, lung function, laboratory values like IgE and eosinophil granulocytes, asthma symptoms, medication use, smoking status, and additional treatments. This data is collected at a baseline visit and then annually for up to 15 years. Each participant receives a unique study ID to protect privacy, with personal and health data stored securely on separate servers. During the study, patients will be regularly monitored for asthma symptom control, with assessments at baseline, four months, and yearly thereafter for up to 15 years. Researchers will track symptoms, medication use, exacerbations, lung function, and laboratory markers to better understand severe asthma's course and treatment outcomes. This long-term follow-up aims to improve care by providing robust data on severe asthma patients.